眶內霉菌感染一例并文獻復習_West China Medical Journal

Authors：

周娟 ¹ , 張勤 ¹ , 張麗娟 ² ,  鄒曉毅 ¹

Corresponding?author：

鄒曉毅, Email: 54522247@qq.com

Keywords：

眶內感染; 霉菌

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【摘要】　目的　報道眶內霉菌感染一例。　方法　 2011年3月4日收治1例眶內霉菌感染患者，結合文獻分析其臨床特點及診治方法。　結果　患者為47歲女性，有霉菌性鼻竇炎病史，右眼腫脹、視物模糊。經抗真菌治療，病情穩定出院；后多次復發入院，且出現肝腎功能損害。經抗真菌、保肝、保腎、對癥治療，病情穩定出院。　結論　眶內霉菌感染多系鼻竇炎擴散而來，易復發，療程較長，治療過程中應監測肝腎功能。

Citation： 周娟,張勤,張麗娟,鄒曉毅. 眶內霉菌感染一例并文獻復習. West China Medical Journal, 2011, 26(12): 1878-1879. doi: Copy

1.	Türel O. Newer antifungal agents[J]. Expert rev anti infect ther, 2011, 9(3): 325-338.
2.	Rapidis AD. Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment:perspectives from a maxillofacial surgeon[J]. Clin Microbiol Infect, 2009,15(Suppl 5): 98-102.
3.	Spellberg B, Fu Y, Edwards JE Jr, et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice[J]. Antimicrob Agents Chemother, 2005, 49(2): 830-832.
4.	Walsh T, Anaissie E, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America[J]. Clin Infect Dis, 2008, 46(3): 327-360.
5.	Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents[J]. Clin Infect Dis, 2011, 52(5): 648-653.
6.	Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis[J]. N Engl J Med, 2002, 347(6): 408-415.
7.	Boucher HW, Groll AH, Chiou CC, et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy[J]. Drugs, 2004, 64(18): 1997-2020.
8.	Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes[J].Clin Infect Dis, 2008, 46(2): 201-211.

1. 　Türel O. Newer antifungal agents[J]. Expert rev anti infect ther, 2011, 9(3): 325-338.
2. 　Rapidis AD. Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment:perspectives from a maxillofacial surgeon[J]. Clin Microbiol Infect, 2009,15(Suppl 5): 98-102.
3. 　Spellberg B, Fu Y, Edwards JE Jr, et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice[J]. Antimicrob Agents Chemother, 2005, 49(2): 830-832.
4. 　Walsh T, Anaissie E, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America[J]. Clin Infect Dis, 2008, 46(3): 327-360.
5. 　Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents[J]. Clin Infect Dis, 2011, 52(5): 648-653.
6. 　Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis[J]. N Engl J Med, 2002, 347(6): 408-415.
7. 　Boucher HW, Groll AH, Chiou CC, et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy[J]. Drugs, 2004, 64(18): 1997-2020.
8. 　Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes[J].Clin Infect Dis, 2008, 46(2): 201-211.

West China Medical Journal

眶內霉菌感染一例并文獻復習

Abstract Full text Figures/Tables Video References Cited by

Format

Content